Trial Profile
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2 microg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA. A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12 microg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Carmoterol (Primary) ; Formoterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 23 Jul 2011 New trial record